Isotechnika releases shareholder letter

In a letter to shareholders issued today, Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster explains the company’s decision to move its voclosporin drug into Phase 3 clinical trials for the prevention of kidney transplant rejection.  He outlines the market opportunity, the scientific rationale and the clinical support for the transplantation indication as well as laying [...]

GeneNews holders okay stock consolidation

Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe that [...]

Isotechnika receives positive scientific advice in Europe for voclosporin

Isotechnika Pharma (TSX:ISA) said it has received positive Scientific Advice from the European Medicines Agency for a proposed Phase 3 clinical trial protocol of its drug, voclosporin, after the agency reviewed the study design and endpoints for the proposed clinical study.   This ensures that no major objections regarding the design of the study or the [...]

Afexa gets promising results in cholesterol management

Afexa Life Sciences (TSX:FXA), the maker of COLD-FX, has achieved promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan, on cholesterol management. The open label and proof of concept study explored the safety and optimum dosing range for Dilexaponan in 39 patients with elevated total cholesterol levels. Dilexaponan is a [...]

Cangene taps Sedor as CEO

Cangene (TSX:CNJ) has named John Sedor as president and CEO, effective Sept. 12, replacing Dr. John Langstaff, who stepped down last January to pursue personal interests. CFO Michael Graham, who has also been serving as interim president and CEO during the board’s search process, will continue in his role as CFO. Mr. Sedor most recently [...]

Paladin eyes Mexico and Brazil for expansion

Pharmaceutical distributor Paladin Labs (TSX:PLB) has set its sights on moving into Mexico and Brazil as it continues its strategy of expanding internationally to complement its growth in Canada. “I would like to be in more geographies, and we’re keenly interested in Mexico and Brazil and looking to do something there,” CEO Jonathan Goodman says [...]

Cipher’s isotretinoin yields positive trial results

Cipher Pharmaceuticals (TSX:DND) has reported top-line safety and efficacy results from the Phase 3 safety study of its CIP-ISOTRETINOIN treatment for severe, nodular acne. From a safety perspective, the top-line data was positive showing no overall statistical differences in the adverse event profile, comparing  CIP-ISOTRETINOIN to a commercially available isotretinoin product in the 925-patient study. The [...]

World-renowned ophthalmologist, Dr. Marguerite McDonald, on managing dry eye patients with TearLab

In an interview with Ophthalmology Web, Dr. Marguerite McDonald discusses the benefits of incorporating the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity System to manage dry eye patients more effectively. Dr. McDonald said that having an objective measurement provided by the TearLab device creates efficiencies in dry eye patient management, as well as providing practice differentiation. Dry eye [...]

Ondine group wins award for anti-microbial project

Ondine Biomedical (TSX,AIM:OBP) in collaboration with University College London professors Ivan Parkin and Michael Wilson, has been awarded a Medical Research Council Developmental Pathway Funding Scheme Award of one million pounds to develop a light-activated anti-microbial application for the prevention of catheter-associated infections such as urinary tract infections. The 2 1/2-year project is scheduled to begin on [...]

Dundee upgrades YM to “buy, venture risk”

Dundee Securities has upgraded YM BioSciences (TSX:YM; Amex:YMI) to “buy, venture risk” from “under review” based on the growing focus of JAK-1/2 inhibitors and the potential that may exist to differentiate YM’s CYT387 drug candidate in the space. Analyst David Martin writes that YM’s release of early data this week “suggests that CYT387 may provide [...]

Next Page »